Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1730206 | 0.95 | LMNA (0.50) | KMT2AMEN1LMNASLC6A2SLC6A3 | |
| SCHEMBL1731232 | 0.95 | KMT2A (0.43) | KMT2AMEN1LMNASLC6A2SLC6A3 | |
| SCHEMBL1732252 | 0.95 | KMT2A (0.43) | KMT2AMEN1LMNASLC6A2SLC6A3 | |
| SCHEMBL1733022 | 0.94 | KDM4E (0.49) | KMT2AMEN1LMNAMAPTNPSR1 | |
| SCHEMBL1731762 | 0.94 | MAPT (0.43) | KMT2AMEN1MAPTNPSR1KDM4E | |
| SCHEMBL1731673 | 0.93 | KMT2A (0.42) | KMT2AMEN1LMNASLC6A2SLC6A3 | |
| SCHEMBL1731344 | 0.92 | RAB9A (0.49) | KMT2AMEN1LMNASLC6A2SLC6A3 | |
| SCHEMBL1732286 | 0.92 | PTPN1 (0.44) | KMT2AMEN1LMNASLC6A2SLC6A3 | |
| SCHEMBL1732980 | 0.91 | ELANE (0.44) | KMT2AMEN1LMNASLC6A2SLC6A3 | |
| SCHEMBL1732504 | 0.91 | MMP12 (0.45) | KMT2AMEN1LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492780-B1 | 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2011-11-23 | — | — | EP | claimed |
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | NOVARTIS AG (CH) | 2008-06-12 | — | — | US | claimed |
| US-7291635-B2 | 5-substituted 1,1-dioxo-1,2,5,-thiadiazolidin-3-one derivatives | NOVARTIS AG (CH) | 2007-11-06 | — | — | US | claimed |
| JP-2005535568-A | — | — | 2005-11-24 | — | — | JP | claimed |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | NOVARTIS AG (CH) | 2005-04-28 | — | — | US | claimed |
| EP-1492780-A1 | 5-SUBSTITUTED 1,1-DIOXO-[1,2,5]THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | Novartis AG (CH) | 2005-01-05 | — | — | EP | claimed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | claimed |
| WO-2003082841-A1 | 5-SUBSTITUTED 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | claimed |
| EP-1492780-B1 | 5-SUBSTITUTED 1,1-DIOXO-¬1,2,5 THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS | NOVARTIS AG (CH) | 2011-11-23 | — | — | EP | disclosed |
| EP-2341049-A1 | 5-substituted 1,1-dioxo-[1,2,5]thiazolidine-3-one derivatives as PTPASE 1B inhibitors | Novartis AG (CH) | 2011-07-06 | — | — | EP | disclosed |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | COPPOLA GARY MARK | 2004-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139576-A1 | 5-Substituted 1,1-Dioxo- 1,2,5- Thiadiazolidin-3-One Derivatives | PTPRS, PTPRJ, IRS1 | KMT2A 2902/4885MEN1 4338/4885LMNA 4787/4885 |
| US-20050090502-A1 | Protein tyrosine phosphatase 1B inhibitors alone or incombination with other antidiabetic, antilipemic, anticholesterol or hypotensive agents | PTPRS, PTPMT1, PTPN1 | KMT2A 3782/4885MEN1 4482/4885LMNA 4768/4885 |
| US-20040023974-A1 | Cyclic sulfamide derivatives and methods of use | PTPRS, PTPA, PTPMT1 | KMT2A 2311/4885MEN1 4365/4885LMNA 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.